Correlation between macular vessel density and number of intravitreal anti-VEGF agents for macular edema associated with branch retinal vein occlusion

Ryo Tomita¹, Takeshi Iwase¹,²*, Kensuke Goto¹, Kentaro Yamamoto¹, Eimei Ra¹ & Hiroko Terasaki¹

We evaluated whether the reduction of macular vessel density was correlated with the number of intravitreal injections of anti-vascular endothelial growth factor (VEGF) agents in eyes with a branch retinal vein occlusion (BRVO). The mean vessel density was determined by optical coherence tomography angiography in 29 eyes with macular edema associated with a BRVO. Our results showed that the mean vessel density in the group that had a resolution of the macular edema after one anti-VEGF injection was significantly higher than that in the group that had a recurrence of the macular edema (P = 0.028). Single regression analysis showed that the number of intravitreal injections was significantly correlated with the reduction of the modified vessel density (r = -0.421, P = 0.023) and systemic hypertension (r = 0.377, P = 0.044). Multiple stepwise regression analysis showed that the reduction of the modified vessel density (β = -0.442, P = 0.009) and hypertension (β = 0.403, P = 0.016) were independent factors associated with the number of intravitreal injections. We conclude that the vessel density reduction can be used to predict whether recurrences of the macular edema will develop after the initial anti-VEGF injection in eyes with macular edema associated with a BRVO.

A branch retinal vein occlusion (BRVO) is a relatively common retinal vascular disorder in elderly individuals, and it can lead to visual dysfunction¹. The most frequent cause of the visual impairments in eyes with a BRVO is macular edema². There are several treatment options for the macular edema, e.g., laser photocoagulation³,⁴, intravitreal injection of steroids⁵, subtenon injection of triamcinolone acetonide (STTA)⁶, dexamethasone intravitreal implant⁷, and vitrectomy⁸. It was recently reported that the intravitreal injections of anti-vascular endothelial growth factor (VEGF) agents, such as bevacizumab⁹,¹⁰, ranibizumab¹¹, or aflibercept¹², were more effective in resolving the macular edema and improving the best-corrected visual acuity (BCVA) than the other treatments.

However, frequent recurrences of the macular edema can occur after an anti-VEGF injection and repeated injections are required¹³. Accordingly, clinicians want to know how many intravitreal injections will be necessary to achieve a complete remission of the macular edema at the early phase of the treatment regimen.

Several factors have been reported to be associated with the recurrences of the macular edema after the injection of an anti-VEGF agent, e.g., initial central retinal thickness (CRT), age, and several other factors¹⁴–¹⁹. However, it is still difficult to predict the number of recurrences even with knowledge of these factors.

The recent development of optical coherence tomography angiography (OCTA) has allowed clinicians to measure the retinal and choroidal blood flow noninvasively. Importantly, earlier studies have shown that OCTA is a reliable technique to evaluate vascular disorders including those associated with a BRVO²⁰–²². It has been reported that eyes with incomplete vessel loss were more likely to have recurrences of the macular edema than eyes with severe vessel loss in eyes with BRVO²³,²⁴. In addition, eyes with a greater reduction in the vessel density determined by OCTA have fewer recurrences of the macula edema²⁶,²⁷. However, the exact

¹Department of Ophthalmology, Nagoya University Graduate School of Medicine, Nagoya, Japan. ²Department of Ophthalmology, Akita University Graduate School of Medicine, Akita, Japan. *email: tiwase@med.nagoya-u.ac.jp
with a range of 46–87 years. The mean pre-treatment BCVA was 0.30 pre-treatment CFT was 445.1 µm treated with intravitreal aflibercept (IVA).

The baseline clinical characteristics of the 29 eyes are summarized in Table 1. The mean age was 66.7 years macular edema secondary to a BRVO and treated with intravitreal injections of anti-VEGF agents were studied. In the end, 29 eyes with macular edema to the first intravitreal injection was 8.1 weeks in the resolved group and 6.1 ± 8.0 weeks in the recurrence group. The mean interval from the diagnosis of macular edema was considered to have occurred when the central retinal thickness was >300 µm.

Results

Demographics of patients. Three eyes were excluded due to a prior vitrectomy; one eye that had a BRVO in both the superior and inferior hemispheres and 1 eye that had diabetic retinopathy. In the end, 29 eyes with macular edema secondary to a BRVO and treated with intravitreal injections of anti-VEGF agents were studied. The baseline clinical characteristics of the 29 eyes are summarized in Table 1. The mean age was 66.7 ± 11.5 years with a range of 46–87 years. The mean pre-treatment BCVA was 0.30 ± 0.27 logMAR units (20/40) and the mean pre-treatment CFT was 445.1 ± 112.0 µm. Six eyes were treated with intravitreal ranibizumab (IVR), and 23 were treated with intravitreal aflibercept (IVA).

Total number of intravitreal injections. The mean of the total number of the intravitreal injection was 1.9 ± 1.1 times in the 29 eyes. The resolved group had 13 eyes, and the recurrence group had 16 eyes. Eleven eyes had two, 3 eyes had three, 1 eye had four, and 1 eye had 6 repeated intravitreal injection of IVR or IVA. The mean of the total number of the injections in the recurrence group was 2.6 ± 1.1.

Comparisons between resolved group and recurrence group. The clinical characteristics of the resolved group and the recurrence group are summarized in Table 2. The mean interval from the diagnosis of macular edema to the first intravitreal injection was 8.1 ± 8.1 weeks in the resolved group and 6.1 ± 8.0 weeks in the recurrence group. A small amount of subretinal macular hemorrhage was observed in one case in both groups. There were no significant differences in the clinical characteristics except that the mean age of the recurrence group was significantly older than the resolved group (P = 0.021).

Values of different parameters obtained by OCTA. The mean superficial FAZ area after the first injection was 0.28 ± 0.10 mm². The mean reduction in the vessel density was 19.8 ± 28.1% in the resolved group (Fig. 1) and 5.87 ± 17.2% in the recurrence group (Fig. 2) at 1 month after the first intravitreal injection. The difference in the mean percentage reduction between the two groups was not significant. On the other hand, the mean modified vessel density reduction was 37.4 ± 27.5% in the resolved group which was significantly higher than the 17.5 ± 18.4% in the recurrence group (P = 0.028; Fig. 3).

Correlations between number of injections and other parameters. Single regression analyses showed that the number of the intravitreal injections was significantly correlated with the reduction of the modified vessel density (r = −0.421, P = 0.023) and with the systemic hypertension (r = 0.377, P = 0.044; Table 3; Fig. 4). However, the reduction in the vessel density, the pre-treatment BCVA, and the pre-treatment CFT were not significantly correlated with the number of injections. The reduction of the modified vessel density was significantly correlated with the ratio of inner retinal layer thickness of the modified affected area to the unaffected area (r = −0.496, P = 0.006; Fig. 5). Multiple stepwise regression analyses showed that the reduction in the modified vessel density (β = −0.442, P = 0.009) and systemic hypertension (β = 0.403, P = 0.016) were independent factors significantly associated with the number of injections (Table 4).

Table 1. Baseline characteristics of subjects. IOP: intraocular pressure, LogMAR: logarithm of the minimum angle of resolution, CFT: central foveal thickness.
of IVR injections for 12 months in eyes with BRVO. However, the affected sector included areas with normal vessel reduction between the two groups. These findings indicate that it is not easy to evaluate accurately the vessel reduction in the macular region in eyes with a BRVO.

Table 2. Baseline characteristics of resolved group and recurrence group. LogMAR: logarithm of the minimum angle of resolution, CFT: central foveal thickness, FAZ: foveal avascular zone.

| Parameter                          | Resolved group | Recurrence group | P Value |
|-----------------------------------|----------------|------------------|---------|
| **Baseline**                      |                |                  |         |
| Age (years)                       | 61.3 ± 10.7    | 71.2 ± 10.9      | 0.021   |
| Sex (male/female)                 | 5/8            | 10/6             | 0.198   |
| Hypertension (patients)           | 3              | 8                | 0.135   |
| Dyslipidemia (patients)           | 0              | 3                | 0.153   |
| Diabetes mellitus (patients)      | 0              | 1                | 0.552   |
| Period from diagnosis to first injection (weeks) | 8.12 ± 8.13   | 6.14 ± 8.03      | 0.517   |
| Visual acuity (LogMAR)            | 0.35 ± 0.37    | 0.26 ± 0.17      | 0.428   |
| CFT (µm)                          | 455 ± 127      | 438 ± 106        | 0.696   |
| **One month after first injection** |              |                  |         |
| Visual acuity (LogMAR)            | 0.24 ± 0.34    | 0.15 ± 0.14      | 0.362   |
| CFT (µm)                          | 215 ± 37.2     | 230 ± 27.9       | 0.223   |
| Vessel density reduction rate (%) | 19.8 ± 28.1    | 5.87 ± 17.2      | 0.113   |
| Modified vessel density reduction rate (%) | 37.4 ± 27.5 | 17.5 ± 18.4    | 0.028   |
| Area of FAZ (mm²)                 | 0.32 ± 0.09    | 0.25 ± 0.10      | 0.070   |
| **Six month after first injection** |            |                  |         |
| Visual acuity (LogMAR)            | 0.18 ± 0.34    | 0.11 ± 0.12      | 0.524   |
| Total number of injections (times) | 1.0           | 2.56 ± 1.09      | < 0.001 |

Discussion

We evaluated the reduction of macular vessel density and found that the reduction of the modified vessel density in the resolved group was significantly higher than that in the recurrence group. It was also significantly correlated with the number of intravitreal anti-VEGF injections during the follow-up period. These findings indicate that the eyes with a greater loss of macular capillaries were more likely to have a fewer number of recurrences of macular edema and fewer number of injections.

The current strategy for the treatment of macular edema secondary to a BRVO is mainly intravitreal injection of anti-VEGF agents. Actually, many large-scale clinical trials have clearly demonstrated a rapid resolution of macular edema and a significant improvement of the visual acuity by the anti-VEGF agents compared with other treatment, e.g. STTA or laser treatment. However, one of the inherent problems of anti-VEGF therapy is that frequent recurrences can occur within a period of a few months after the injection and multiple injections of the agents are required for the recurrences in many cases. Accordingly, it is important to determine a method to predict recurrences at the early phase of the treatment. This would then allow the clinician to strategize the best treatment protocol.

Several factors have been reported to be related to the recurrences of macular edema in eyes with BRVO, e.g., the CRT. However, the CRT was not significantly correlated with the number of injection and no significant difference in the CRT was found between the resolved and recurrence group. It has been reported that the vessel density was decreased in both the superficial and deep vessel capillary plexuses, and the gap between the surface and deep capillary plexus is significantly greater in the recurrent macular edema group. In addition, Hasegawa et al. divided the 3 × 3 mm image obtained by OCTA at 1 month after IVR into superior and inferior sectors and calculated the percentage of reduction in the vessel density by dividing the affected sector by the unaffected sector. They found that eyes with a larger degree of vessel reduction had fewer recurrences and lower percentage of IVR injections for 12 months in eyes with BRVO. However, the affected sector included areas with normal vasculature and normal FAZ as well as the unaffected sector. We evaluated the vessel density reduction percentage by comparing the affected sector (1.57 mm²) and not affected sector using the ETDRS grid, which is smaller than the area (4.5 mm²) reported by Hasegawa et al. However, our results showed no significant difference in the vessel density reduction rate between the resolved group and the recurrence group, and no significant correlation between the vessel density reduction rate and the number of injections. One of the reasons for the lack of a significant difference between the groups is that the area still included areas with normal vasculature even in the affected sector, although the measured area was smaller than that reported by Hasegawa. This situation could lead to an underestimation in the degree of vessel density reduction and result in no significant difference in the vessel density reduction between the two groups. These findings indicate that it is not easy to evaluate accurately the vessel reduction in the macular region in eyes with a BRVO.

Then, the center of the ETDRS grid (0.79 mm²) was placed at the region where the retinal vessel density of the affected retina was the lower, and we determined the modified vessel density reduction rate. Our results showed that the degree of reduction of the modified vessel density in the resolved group was higher than that in the recurrence group, and it was significantly correlated with the number of anti-VEGF injections.

It is more likely that the modified vessel density reduction is related to the degree of vessel disruption because the measured area was smaller and included only the occluded region in most eyes. Actually, previous studies have reported that a severe reduction in the macular vasculature may cause the elimination of the source of the vessel density reduction.
leakage which would then be fewer recurrence of macular edema. In addition, eyes with a greater defect of macular capillaries may lead to atrophy of the inner retinal layer, lower oxygen demand, and lower VEGF production. In fact, our study showed that the modified vessel density rate was significantly correlated with the

Figure 1. Representative case with macular edema secondary to a branch retinal vein occlusion (BRVO) that was resolved by single intravitreal injection of anti-VEGF agent during the follow-up period. (A) Fundus photograph showing major BRVO at the first visit. (B) Vertical OCT image shows the macular edema at the initial visit, but the edema was resolved throughout the follow-up period after the anti-VEGF injection. (C,D) Fluorescein angiogram showing sparse hyperfluorescence corresponding to the occluded region at the initial visit. (E) OCTA image showing wide non-perfused area in the occluded area, and the vessel density was significantly lower in the affected area at 1 month after the first injection. The modified vessel density reduction was 82.5%. (F) The vessel density reduction rate was 68.8%.

leakage which would then be fewer recurrence of macular edema. In addition, eyes with a greater defect of macular capillaries may lead to atrophy of the inner retinal layer, lower oxygen demand, and lower VEGF production. In fact, our study showed that the modified vessel density rate was significantly correlated with the
ratio of inner retinal layer thickness on the affected area to the unaffected area 6 months after the first injection. This result suggests that eyes with a larger vessel density reduction should have fewer leaking vessels which is the cause of the macular edema and may reduce oxygen consumption in the inner retina leading to a lower rate of recurrences and fewer anti-VEGF injections. Taken together, the modified vessel density reduction at 1 month
after initial the anti-VEGF injection would be a useful parameter to predict the number of anti-VEGF injections at the early phase of the treatment in eyes with BRVO.

Our result showed that a history of systemic hypertension was correlated with the number of anti-VEGF injections. It has been reported that hypertension is a risk factor for the development of a RVO32,33. Kida reported three cases in which there was an improvement of the macular edema after a treatment of only the systemic hypertension in patients with macular edema secondary to RVO34. These results suggest that RVO might recur more often in patients with hypertension. Our patients with hypertension were treated, and the blood pressure was decreased to normal range during the course of this study. This might explain the observation that the blood pressure was not significantly correlated with the number of injections.

Our study has several limitations. First, this was a retrospective study. Second, intravitreal injections were not unified with the use of either aflibercept or ranibizumab. Third, we selected the location to measure the modified blood vessel density reduction rate manually. Fourth, we did not evaluate the leakage from the vessels using FA, and thus the association between the time of injection and the leakage is unclear. Fifth, the evaluations of the retinal vasculature in OCTA is performed only on the superficial capillary plexus. However, the resolution in deep layer detected by commercially available OCTA is still not good, and it is difficult to obtain accurate evaluations using the deep capillary plexus parameters. Further prospective studies using a larger number of subjects using one anti-VEGF agent and the analyses of both the superficial and deep capillary areas determined by OCTA will be necessary to confirm the association between the retinal vasculature and the number of injection of anti-VEGF agents.

Table 3. Results of spearman's rank correlation coefficient between the total number of injections and clinical parameters. CFT: central foveal thickness, FAZ: foveal avascular zone.
In conclusion, the modified vessel reduction rate was higher in eyes that had a resolution of the macular edema after a single injection of an anti-VEGF agent. It was significantly negatively correlated with the total number of intravitreal injections. These results indicate that the modified vessel density rate would be a useful parameter to use to predict the number of anti-VEGF injections for macular edema secondary to a BRVO.

Figure 4. Relationship between the total number of intravitreal injections of anti-VEGF agents until 6 months after the first injection and the modified vessel density reduction rate 1 month after first injection. The total number of intravitreal injections was significantly correlated with the modified vessel density reduction rate ($r = -0.421, P < 0.023$).

Figure 5. The reduction of the modified vessel density was significantly correlated with the ratio of inner retinal layer thickness of the modified affected area to the unaffected area where the modified vessel density rate was measured using OCTA. ($r = -0.496, P = 0.006$).

| Variable                                      | $\beta$  | $P$ Value |
|-----------------------------------------------|----------|-----------|
| Total number of injections                    |          |           |
| Modified vessel density reduction rate        | -0.442   | 0.009     |
| Hypertension                                  | 0.403    | 0.016     |
| Sex                                           | -0.225   | 0.180     |
| CFT 1 month after first injection            | 0.169    | 0.315     |
| Dyslipidemia                                  | 0.087    | 0.601     |
| Diabetes mellitus                             | -0.086   | 0.601     |
| FAZ                                           | -0.063   | 0.706     |
| Visual acuity 1 month after first injection   | 0.026    | 0.879     |
| Age                                           | 0.009    | 0.957     |

Table 4. Results of multiple stepwise regression analysis for independence of factors contributing to the number of injections. CFT: central foveal thickness, FAZ: foveal avascular zone.

In conclusion, the modified vessel reduction rate was higher in eyes that had a resolution of the macular edema after a single injection of an anti-VEGF agent. It was significantly negatively correlated with the total number of intravitreal injections. These results indicate that the modified vessel density rate would be a useful parameter to use to predict the number of anti-VEGF injections for macular edema secondary to a BRVO.
Patients and Methods

Ethics statement. This was a single-center, retrospective study, and the procedures were approved by the Ethics Committee of the Nagoya University Hospital, Nagoya, Japan. The procedures conformed to the tenets of the Declaration of Helsinki. A signed written informed consent was obtained from all patients for the intravitreal injections.

Patients. All of the patients were examined at the Nagoya University Hospital between January 2016 and May 2018. The medical records of patients with macular edema that was associated with a BRVO, and whose spectral-domain OCT (SD-OCT) images showed that the edema extended to the fovea were analyzed. The macular edema was treated with intravitreal ranibizumab (IVR) or aflibercept (IVA) injections. The patients underwent the OCTA examinations when the macular edema was resolved at 1 month after the first intravitreal injection. They were then followed for at least 6 months after the injection, and they received repeat IVR or IVA when the central foveal thickness was ≥300 µm. The same anti-VEGF agent as the first injection was injected to treat the recurrence of the macular edema.

The patients were classified into 2 groups; patients who had only one intravitreal injection were classified as the resolved group, and patients who required more than one intravitreal injection were classified as the recurrence group. The total number of intravitreal injections after the first injection for 6 months was used for the statistical analyses.

All of the patients had a comprehensive ophthalmic examination including measurement of the best-corrected visual acuity (BCVA), fundus examinations by indirect ophthalmoscopy, slit-lamp biomicroscopy, and fundus photography. The Snellen BCVA values were converted to the logarithm of the minimum angle of resolution (logMAR) units for the statistical analyses.

Exclusion criteria. Patients with other macular diseases, such as age-related macular degeneration, myopic choroidal neovascularization, epiretinal membrane, diabetic retinopathy, history of other ocular diseases, rhegmatogenous retinal detachment, and severe cataract, were excluded.

Retinal microvasculature imaging by OCTA. The Angio Plex® OCTA (Zeiss Meditec Inc, Germany) was used to obtain 3 × 3-mm en face images of the microvasculature centered on the fovea. The boundaries of the superficial capillary plexus extended from 3 µm beneath the internal limiting membrane (ILM) to 15 µm beneath the inner plexiform layer (IPL). All of the scans were reviewed by two graders (RT and TI), and the eyes with poor image quality caused by blink artifacts, poor fixation leading to motion or doubling artifacts, and media opacities that obscured the view of the vasculature, were excluded.

The superficial OCTA image of 3 mm diameter centered on the fovea was automatically divided into 5 sectors, e.g., the fovea of 0.79 mm², the inferior, superior, nasal, and temporal (all, 1.57 mm²) sectors as defined by the Early Treatment Diabetic Retinopathy Study (ETDRS) grid. The vessel density in each of the ETDRS sector was automatically measured by the embedded software of the OCTA device (version 10).

The ETDRS grid was centered on the fovea, and the vessel density of the superior or inferior sectors that was affected by the BRVO was defined as the affected vessel density sectors and the vessel density of the unaffected sectors was defined as the unaffected vessel density²⁷.

The reduction in the vessel density (%) was calculated as:

\[
\text{Reduction of vessel density} \% = \left(1 - \frac{\text{affected vessel density}}{\text{unaffected vessel density}}\right) \times 100.
\]

We then displaced the center of the ETDRS grid to the area where the vessel density was most decreased on the affected hemisphere and defined the vessel density of the area as the modified affected vessel density. In addition, we measured it at a horizontally symmetrical position containing fovea and defined this as the modified unaffected vessel density. The reduction in the modified vessel density (%) was defined as:

\[
\text{Reduction of modified vessel density} \% = \left(1 - \frac{\text{modified affected vessel density}}{\text{modified unaffected vessel density}}\right) \times 100.
\]

The areas of the superficial foveal avascular zone (FAZ) were determined after the resolution of the macular edema with the software embedded in the OCTA device.

Analyses of OCT images. A Spectralis® SD-OCT instrument (Heidelberg Engineering, Heidelberg, Germany) was used to obtain horizontal cross-sectional images that were recorded before and 1 month after the treatment. The central foveal thickness (CFT) was defined as the thickness between the surface of the ILM and the outer border of the retinal pigment epithelium (RPE) centered on the fovea. Six months after the first injection, the ratio of the inner retinal layer thickness at the center of the affected area to the unaffected areas where the modified vessel density rate was measured using OCTA.

Statistical analyses. The values are presented as the means ± standard deviations (SDs). Spearman’s rank tests were used to determine the significance of the correlation coefficients between each parameter and the number of intravitreal injections. Forward stepwise regression analyses were performed to identify the factors significantly correlated with the number of the intravitreal injections. Independent sample t tests, nonparametric Mann-Whitney U tests, and Chi-squared tests were used to determine the significance of the differences in the variables between the resolved group and the recurrence group. All statistical analyses were performed with the Statistical Package for Social Sciences for Windows 25.0 (SPSS Inc, Chicago, Illinois, USA).

Received: 31 July 2019; Accepted: 22 October 2019; Published online: 08 November 2019
References
1. Rogers, S. L. et al. Natural history of branch retinal vein occlusion: an evidence-based systematic review. Ophthalmology. 117, 1094–1101 e1095 (2010).
2. Ehlers, J. P. et al. Therapies for Macular Edema Associated with Branch Retinal Vein Occlusion: A Report by the American Academy of Ophthalmology. Ophthalmology. 124, 1412–1423 (2017).
3. Argon laser scatter photocoagulation for prevention of neovascularization and vitreous hemorrhage in branch vein occlusion. A randomized clinical trial. Branch Vein Occlusion Study Group. Arch Ophthalmol. 104, 34–41 (1986).
4. Argon laser photocoagulation for macular edema in branch vein occlusion. The Branch Vein Occlusion Study Group. Am J Ophthalmol. 98, 271–282 (1984).
5. Scott, I. U. et al. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with standard care to treat vision loss associated with macular Edema secondary to branch retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 6. Arch Ophthalmol. 127, 1115–1128 (2009).
6. Gurram, M. M. Effect of posterior sub-tenon triamcinolone in macular edema due to non-ischemic vein occlusions. J Clin Diagn Res. 7, 2821–2824 (2013).
7. Hattenbach, L. O. et al. Head-to-head comparison of ranibizumab PRN versus single-dose dexamethasone for branch retinal vein occlusion (COMRADE-B). Acta Ophthalmol. 96, e10–e18 (2018).
8. Sato, S. et al. Outcomes of microincision vitrectomy surgery with internal limiting membrane peeling for macular edema secondary to branch retinal vein occlusion. Clin Ophthalmol. 9, 439–444 (2015).
9. Kondo, M. et al. Intravitreal injection of bevacizumab for macular edema secondary to branch retinal vein occlusion: results after 12 months and multiple regression analysis. Retina. 29, 1242–1248 (2009).
10. Leitritz, M. A. et al. Grid laser photocoagulation for macular oedema due to branch retinal vein occlusion in the age of bevacizumab? Results of a prospective study with crossover design. Br J Ophthalmol. 97, 215–219 (2013).
11. Campochiaro, P. A. et al. Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology. 117, 1102–1112 e1101 (2010).
12. Campochiaro, P. A. et al. Intravitreal aflibercept for macular edema following branch retinal vein occlusion: the 24-week results of the VIBRANT study. Ophthalmology. 122, 538–544 (2015).
13. Miwa, T. et al. Ranibizumab for macular edema after branch retinal vein occlusion: One initial injection versus three monthly injections. Retina. 37, 702–709 (2017).
14. Yamada, R. et al. Predictive factors for recurrence of macular edema after successful intravitreal bevacizumab therapy in branch retinal vein occlusion. Jpn J Ophthalmol. 59, 389–393 (2015).
15. You, J. H., Ahn, J., Oh, J., Cha, J. & Kim, S. W. Risk factors of recurrence of macular edema associated with branch retinal vein occlusion after intravitreal bevacizumab injection. Br J Ophthalmol. 101, 1334–1339 (2017).
16. Tsuboi, K., Ishida, Y. & Kamei, M. Gap in Capillary Perfusion on Optical Coherence Tomography Angiography Associated With Persistent Macular Edema in Branch Retinal Vein Occlusion. Invest Ophthalmol Vis Sci. 58, 2038–2043 (2017).
17. Hasegawa, T., Murakawa, S., Maruko, I., Kogure-Katakura, A. & Iida, T. Correlation between reduction in macular vessel density and frequency of intravitreal ranibizumab for macular oedema in eyes with branch retinal vein occlusion. Br J Ophthalmol. 103, 72–77 (2019).
18. Hasegawa, T., Takahashi Y, Maruko I, Kogure A & Iida T. Macular vessel reduction as predictor for recurrence of macular oedema requiring repeat intravitreal ranibizumab injection in eyes with branch retinal vein occlusion. Br J Ophthalmol. (2018).
19. Kourakos V, Rauscher A & Schmidbauer J. Predictive Value of OCT-Controlled Early Response of Macular Edema Secondary to Retinal Vein Occlusion After Intravitreal Bevacizumab Therapy. Klin Monbl Augenheilkd. (2018).
20. Rispoli, M., Savastano, M. C. & Lombroso, B. Capillary Network Anomalies In Branch Retinal Vein Occlusion On Optical Coherence Tomography Angiography. Retina. 35, 2332–2338 (2015).
21. Adhi, M. et al. Retinal Capillary Network and Foveal Avascular Zone in Eyes With Macular Oedema and Fellow Eyes Analyzed With Optical Coherence Tomography Angiography. Invest Ophthalmol Vis Sci. 57, OCT486–494 (2016).
22. Suzuki, N. et al. Microvascular Abnormalities on Optical Coherence Tomography Angiography in Macular Edema Associated With Branch Retinal Vein Occlusion. Am J Ophthalmol. 161, 126–132 e121 (2016).
23. Finkelstein, D. Ischemic macular edema. Recognition and favorable natural history in branch vein occlusion. Arch Ophthalmol. 110, 1427–1434 (1992).
24. Sakimoto, S. et al. Relationship between grades of macular perfusion and foveal thickness in branch retinal vein occlusion. Clin Ophthalmol. 7, 39–45 (2013).
25. Qian, T., Zhao, M. & Xu, X. Comparison between anti-VEGF therapy and corticosteroid or laser therapy for macular oedema secondary to retinal vein occlusion: A meta-analysis. J Clin Pharm Ther. 42, 519–529 (2017).
26. Pielien, A. et al. Efficacy and safety of intravitreal therapy in macular edema due to branch retinal vein occlusion: a systematic review. PLoS One. 8, e78538 (2013).
27. Feltgen, N. et al. Comparison of ranibizumab versus dexamethasone for macular oedema following retinal vein occlusion: 1-year results of the COMRADE extension study. Acta Ophthalmol. 96, e933–e941 (2018).
28. Heier, J. S. et al. Ranibizumab for macular edema due to retinal vein occlusions: long-term follow-up in the HORIZON trial. Ophthalmology. 119, 802–809 (2012).
29. Samara, W. A. et al. Quantitative Optical Coherence Tomography Angiography Features and Visual Function in Eyes With Branch Retinal Vein Occlusion. Am J Ophthalmol. 166, 76–83 (2016).
30. Schmid, H., Renner, M., Dick, H. B. & Joachim, S. C. Loss of inner retinal neurons after retinal ischemia in rats. Invest Ophthalmol Vis Sci. 55, 2777–2787 (2014).
31. Lim, H. B., Kim, M. S., Jo, Y. J. & Kim, I. J. Prediction of Retinal Ischemia in Branch Retinal Vein Occlusion: Spectral-Domain Optical Coherence Tomography Study. Invest Ophthalmol Vis Sci. 56, 6622–6629 (2015).
32. Petrella, R. J., Bloun, J., Davies, B. & Barbeau, M. Incidence and Characteristics of Patients with Visual Impairment due to Macular Edema Secondary to Retinal Vein Occlusion in a Representative Canadian Cohort. J Ophthalmol. 2012, 723169 (2012).
33. O’Mahoney, P. R., Wong, D. T. & Ray, J. G. Retinal vein occlusion and traditional risk factors for atherosclerosis. Arch Ophthalmol. 126, 692–699 (2008).
34. Kida, T. et al. Treatment of systemic hypertension is important for improvement of macular edema associated with retinal vein occlusion. Clin Ophthalmol. 8, 955–958 (2014).

Acknowledgements
This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.

Author contributions
Contributions of authors: The design and conduct of the study (T.I.); collection of data (T.I., R.T. and K.G.); management, analysis, and interpretation of data (T.I., R.T., E.R. and H.T.); and preparation, review, and approval of the manuscript (T.I., R.T., K.G., K.Y., E.R. and H.T.).
Competing interests
The authors declare no competing interests.

Additional information
Correspondence and requests for materials should be addressed to T.I.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2019